Market Access

Will result from Medicare reforms, despite increased drug uptake.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.

Investigation notes a need for greater transparency in 340B program revenue and strengthened enforcement authority for the Health Resources and Services Administration.

ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.

Blue Fin Group exec speaks on his upcoming feature.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Director of Berkeley Research Group explains changes to 340B moving forward.

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing.

Berkeley Research Group Director discusses what to expect at his upcoming session.

Tirzepatide (Zepbound; Eli Lilly and Company) will hit the US market by the end of 2023 with a list price of $1,059.87.

Study describes how biotech startups can avoid competing with large pharma companies for financing.

HDA research reveals that 95% of pharma transactions move through the traditional distribution channel.

Payers won’t let these products break the bank.

The conference will focus on the full breadth of commercialization strategies and operations.

Boehringer Ingelheim’s unbranded adalimumab-adbm biosimilar will be available at an 81% discount to adalimumab (Humira).

The debate continues as to how government payers should weigh covering healthcare needs versus other budget items.

These programs can negatively impact patients trying to reach their deductible.

The trend is continuing for brands and even for some specialty products.

An analysis by 3 Axis Advisors has found that there is a large variability in pharmacy reimbursement of prescription drugs depending on PBM contracts with insurers. This creates a system with huge inconsistencies on the prices of both generics and branded products.

Nearly 96% of respondents say that this is an issue affecting their respective pharmacy.

Collaboration aims to cut medication costs for patients with conditions ranging from high blood pressure to diabetes.

How drugmakers can navigate the program’s pricing challenges and regulatory developments.

Conditions require a disciplined approach to drug pricing.

Delays could harm older Americans, interest group states.